J Gynecol Oncol.  2022 Sep;33(5):e61. 10.3802/jgo.2022.33.e61.

Current status of hereditary breast and ovarian cancer practice among gynecologic oncologists in Japan: a nationwide survey by the Japan Society of Gynecologic Oncology (JSGO)

• Kobayashi Y
• Masuda K
• Hiraswa A
• Takehara K
• Tsuda H
• Watanabe Y
• Oda K
• Nagase S
• Mandai M
• Okamoto A
• Yaegashi N
• Mikami M
• Enomoto T
• Aoki D
• Katabuchi H
• Working Group on Clinical Practice for Cancer Genomic Medicine and HBOC, Japan Society of Gynecologic Oncology

• KMID: 2537910
• DOI: http://doi.org/10.3802/jgo.2022.33.e61

Abstract

Objective
The practices pertaining to hereditary breast and ovarian cancer (HBOC) in Japan have been rapidly changing owing to the clinical development of poly(ADP-ribose) polymerase inhibitors, the increasing availability of companion diagnostics, and the broadened insurance coverage of HBOC management from April 2020. A questionnaire of gynecologic oncologists was conducted to understand the current status and to promote the widespread standardization of future HBOC management.
Methods
A Google Form questionnaire was administered to the members of the Japan Society of Gynecologic Oncology. The survey consisted of 25 questions in 4 categories: respondent demographics, HBOC management experience, insurance coverage of HBOC management, and educational opportunities related to HBOC.
Results
A total of 666 valid responses were received. Regarding the prevalence of HBOC practice, the majority of physicians responded in the negative and required human resources, information sharing and educational opportunities, and expanded insurance coverage to adopt and improve HBOC practice. Most physicians were not satisfied with the educational opportunities provided so far, and further expansion was desired. They remarked on the psychological burdens of many HBOC managements. Physicians reported these burdens could be alleviated by securing sufficient time to engage in HBOC management, creating easy-to-understand explanatory material for patients, collaboration with specialists in genetic medicine, and educational opportunities.
Conclusion
Gynecologic oncologists in Japan are struggling to deal with psychological burdens in HBOC practice. To promote the clinical practice of HBOC management, there is an urgent need to strengthen human resources and improve educational opportunities, and expand insurance coverage for HBOC management.

Keyword

Hereditary Breast and Ovarian Cancer Syndrome; Obstetrics and Gynecology Department, Hospital; Genetic Testing; Insurance Coverage; Poly(ADP-Ribose) Polymerase Inhibitors